The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Xylyx Bio awarded $2.45M NIH SBIR grant from NIDDK for liver fibrosis drug development
Sep 16, 2024•almost 2 years ago
Contract Type
partnership
New YorkBiotechnologyHealth Care
Description
Xylyx Bio, Inc. has been awarded a $2.45M Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance commercial development of its InMatrico® disease modeling and drug testing platform for liver fibrosis. The award supports the development of a cell-based assay platform to help scientists discover and test drug candidates for liver fibrosis, aiming to address the lack of predictive in-vitro drug testing assays and accelerate the development of improved treatment options for patients with fibrotic liver disease.
Company Information
Company
Xylyx Bio
Location
New York, New York, United States
About
Xylyx Bio, Inc. is a regenerative medicine company that develops pioneering solutions for tissue and organ modeling and repair.
New YorkBiotechnologyHealth Care